Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 developmentScancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3 study for iSCIB1+ and a proposed listing on Nasdaq (the “Merger and Financing Announcement”), it has entered into a loan agreement (the “Loan Agreement”) with certain funds and accounts managed by BlackRock (the “Lender”), for a loan facility of up to US$25,000,000 (the “Loan Facility”).
- Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on September 28, 2026.
- HUTCHMED (China) Limited HONG KONG and SHANGHAI andHUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.
- Astellas Pharma Inc.Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3 study of setidegrasib initiated within six months - TOKYO, Sept. 23, 2026 --...
- Teva Pharmaceutical Industries LtdTeva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ETTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
- Teva Pharmaceutical Industries LtdTeva Releases Q3 2026 Aide MemoireTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website.
- Viking Therapeutics, Inc.Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior NotesViking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other...
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026
- OracleOracle to Advance Cancer Care with New Oncology EHRCompanies: Oracle CorporationOracle Health and Life Sciences Summit – Oracle today announced its Oracle Health Oncology EHR. Building on the capabilities of Oracle's modern,...
- Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational MedicineBreye Therapeutics announces that it has had a paper on its lead asset danegaptide published in the prestigious journal Science Translational Medicine
- CROSSJECT et la BARDA consolident le plan de développement pédiatrique de ZEPIZURE® selon les attentes de la FDA avec un financement renforcé jusqu’en 2030DIJON, France — 23 septembre 2026 – 19 h 00 (CEST) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), Specialty Pharma internationale spécialisée dans le développement d’auto-injecteurs sans aiguille destinés aux situations d’urgence, annonce aujourd’hui que CROSSJECT et la BARDA ont consolidé le plan de développement clinique pour l’indication pédiatrique de ZEPIZURE®, conformément aux recommandations de la FDA. En vertu de la modification n° 4 du contrat n° 75A50122C00031, la BARDA apporte un financement supplémentaire non dilutif de 4,7 millions de dollars pour couvrir ce plan et a prolongé la durée d’exécution jusqu’au 21 juin 2030. Le financement total de la BARDA consacré au développement de ZEPIZURE® s’élève désormais à 48,0 millions de dollars.
- OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified DecisionsANTWERPEN, BELGIUM, Sept 23, 2026 - OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning™, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services. German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning™. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma. Combining innovation, industry knowledge, and integration OMP and PwC run each implementation as a single program. OMP brings Unison Planning™, its AI-enabled platform with built-in industry expertise, connecting to the systems that a manufacturer already runs. PwC's teams lead the implementation, acting as system integrator and working directly alongside the customer's own planners. Both organizations see the same shift across life sciences, consumer goods, and chemicals: manufacturers replacing fragmented planning with a unified end-to-end plan, and looking for a platform and an implementation team that already know their industry. "Process manufacturers face the same planning constraints, whatever their size, and few have spare program capacity to absorb an implementation. That is where the combination of the platform, the industry knowledge, and an integrator who can run the program matters most," said Dieter Sleeuwaert, Senior Vice President Global Alliances at OMP. medac moves from spreadsheets to a single demand plan medac supplies specialty treatments in rheumatology, urology, hematology, and oncology to more than 90 countries, manufacturing at its own European sites. Its planning ran on a mix of spreadsheets, planning functions within its existing ERP system, and a separate tool with limited planning capability. Processes also differed by department and by geography. PwC, medac and OMP started with a focused demand planning release, resulting in an accelerated go-live for German planners ahead of the wider rollout. The remaining geographies, a supply planning layer, and a second release running in parallel with medac's SAP S/4 implementation will follow. "Leading with the demand planning release and holding the solution close to standard is what made it work. That approach transfers to other companies in the sector," said Jörg Zietz, Director, Supply Chain Planning at PwC Germany. PwC and medac on stage in Singapore Dr. Karsten Gentner, Vice President Supply Chain Management and Procurement at medac, and Jörg Zietz of PwC Germany will explain how medac is building the digital backbone for a smarter, more resilient, and AI-ready pharmaceutical supply chain. Their session takes place on October 15, 2026 at the OMP Conference in Singapore. Register for the event. About PwC At PwC, we help clients build trust and reinvent so they can turn complexity into a competitive advantage. We're a tech-forward, people-empowered network with more than 364,000 people in 136 countries and 137 territories. Across audit and assurance, tax and legal, deals and consulting, we help clients build, accelerate, and sustain momentum. About medac The medac Group is committed to improving patients' quality of life worldwide by providing access to the best possible medical therapies. As a globally operating pharmaceutical company headquartered in Germany, we are active in more than 90 countries and employ over 2,000 people worldwide. With production sites in Europe and a focus on rheumatology, urology, hematology, and oncology, medac develops and markets high-quality originator products, generics, and biosimilars. About OMP OMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics, tires, and building products - benefit from using OMP's unique Unison Planning™. Solution and product inquiries Contact OMP +32 3 650 22 11 Media inquiries Kira Perdue (Carabiner) SOURCE: OMP